ABOUT US TEAM PLATFORMS PRODUCTS NEWS JOIN OUR TEAM Sherlock™ CRISPR SARS-CoV-2 The Sherlock™ CRISPR SARS-CoV-2 kit is the first FDA authorized CRISPR-based EUA diagnostic test. The kit is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory tract and bronchoalveolar lavage samples from individuals suspected of COVID-19 by their healthcare provider. This kit provides specific and sensitive identification of SARS-CoV-2. INQUIRE TECHNICAL SUPPORT CENTER (617) 702-6263 support@sherlock.bio Sherlock™ CRISPR SARS-CoV-2 Kit Bringing Speed, Accuracy and Precision to the Fight Against COVID-19. INQUIRE DOWNLOAD BROCHURE SAMPLE PREP Extract RNA from collection device (Upper Respiratory Sample) AMPLIFICATION Loop-mediated isothermal RNA amplification DETECTION CRISPR target-based activation for SARS-CoV-2 ID OUTPUT Reporter - Cleavage based output The Sherlock™ CRISPR SARS-CoV-2 kit is the first EUA CRISPR based diagnostic test intended for the qualitative detection of nucleic acid from SARS-CoV-2. This kit provides specific and sensitive detection of the SARS-CoV-2 virus in upper respiratory tract and bronchoalveolar lavage specimens from individuals suspected of COVID-19 by their healthcare provider. TOP 5 BENEFITS Faster than PCR; approximately 1 hour reaction time Add thousands of tests per day to current lab volume 100% specificity and sensitivity in EUA clinical evaluation Minimal footprint; uses standard laboratory equipment and a microplate reader CRISPR SHERLOCK technology, proven highly sensitive with an LoD of 6.75 cp/uL VTM The Sherlock™ CRISPR SARS-CoV-2 kit is designed to detect fragments in the Open Reading Frame (ORF1ab) gene and the Nucleocapsid (N) gene of SARS-CoV-2. Internal control target human RNase P POP7 gene is used for confirmation of clinical sample extraction in the absence of a positive SARS-CoV-2 result. The assay is comprised of two steps. Step one is RT-LAMP where targeted SARS-CoV-2 genomic RNA is reverse transcribed to DNA then amplified by a strand-displacing DNA polymerase. Step two transcribes the amplified DNA to activate collateral cleavage activity of a CRISPR complex programmed to the target RNA sequence. Cleavage of nucleic acid reporters results in a fluorescent readout detectable by a standard plate reader. MORE INFORMATION BioTek® Synergy™ Neo2 Microplate Reader Instructions for Use Our FAQ Fact Sheet for Healthcare Providers Fact Sheet for Patients PUBLICATIONS SAFETY, LEGAL, QUALITY & USAGE INQUIRE This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens This test has not been FDA cleared or approved This test has been authorized by FDA under an EUA for use by authorized laboratories This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Contact us to learn more about how we are engineering biology to test anywhere, everywhere. 617-612-8209 info@sherlock.bio Sherlock Biosciences 40 Guest Street, 3rd Floor Boston, MA 02135 © 2021 Sherlock Biosciences. All Rights Reserved. Sherlock uses your contact information to update you about Sherlock’s products and services. To learn more about how Sherlock treats your information, please review our privacy policy. Terms of Sale. We use cookies and by using this site or closing this message, you agree to our privacy policy. Allow Scroll to close this message.